Rapid, substantial, and durable improvement in depressive symptoms (MADRS), and functioning (SDS) with AXS-05, sustained over 12 months, (p
Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting
On 6ix: 6ix.com/news/axsome-therapeutics-announces-late-breaking-presentations-of-positive-results-of-the
Watch Axsome Therapeutics' latest callAxsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings CallAxsome Therapeutics' next earnings callAxsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call · Nov 2, 2026 at 8:00 AM ESTRegister
Axsome Therapeutics, Inc. on 6ix
Story so far
- Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
- Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
- Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
Earlier from Axsome Therapeutics
- Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry
- Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry
- Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month
- Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
- Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Later from Axsome Therapeutics
- Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder
- Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting
- Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
- Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders
- Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Follow Axsome Therapeutics into a list and get an email when it puts out news.
Follow Axsome Therapeutics